Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Managemen...(and our competitors. All of these factor...)

Date:2/25/2008

and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A -- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

'/>"/>

SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
2. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
3. Boston Scientific to Participate in Merrill Lynch Conference
4. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
5. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
6. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
7. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
8. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
9. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
10. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
11. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board